Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HSTOOTCMKTS:OREXQOTCMKTS:PREDOTCMKTS:SOAN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHSTOHistogen$0.01-43.5%$0.02$0.05▼$0.55$43K1.1910,369 shs1,050 shsOREXQOrexigen Therapeutics$0.01+35.9%$0.01$0.00▼$0.16$100K4.9880,439 shs60,300 shsPREDPredictive Technology Group$0.00$0.00▼$0.04$32K-0.7762,884 shs17,642 shsSOANAngioSoma$0.00$0.00▼$0.09$32.57M-0.466.74 million shsN/AThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHSTOHistogen0.00%+4,325.00%-34.44%-36.79%-94.10%OREXQOrexigen Therapeutics0.00%0.00%0.00%0.00%0.00%PREDPredictive Technology Group0.00%0.00%0.00%0.00%0.00%SOANAngioSoma0.00%0.00%0.00%0.00%-81.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHSTOHistogenN/AN/AN/AN/AN/AN/AN/AN/AOREXQOrexigen TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APREDPredictive Technology GroupN/AN/AN/AN/AN/AN/AN/AN/ASOANAngioSomaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHSTOHistogen 0.00N/AN/AN/AOREXQOrexigen Therapeutics 0.00N/AN/AN/APREDPredictive Technology Group 0.00N/AN/AN/ASOANAngioSoma 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHSTOHistogen$19K2.25N/AN/A$3.13 per share0.00OREXQOrexigen Therapeutics$33.71M0.00N/AN/AN/A∞PREDPredictive Technology GroupN/AN/AN/AN/AN/AN/ASOANAngioSomaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHSTOHistogen-$10.62M-$2.81N/A∞N/AN/AN/AN/AN/AOREXQOrexigen Therapeutics-$24.52MN/A0.00∞N/AN/AN/AN/AN/APREDPredictive Technology GroupN/AN/A0.00N/AN/AN/AN/AN/AN/ASOANAngioSoma-$540KN/A0.00N/AN/AN/AN/A-1,245.34%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHSTOHistogenN/AN/AN/AN/AN/AOREXQOrexigen TherapeuticsN/AN/AN/AN/AN/APREDPredictive Technology GroupN/AN/AN/AN/AN/ASOANAngioSomaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHSTOHistogenN/AN/AN/AOREXQOrexigen TherapeuticsN/AN/AN/APREDPredictive Technology GroupN/AN/AN/ASOANAngioSomaN/A0.290.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHSTOHistogenN/AOREXQOrexigen TherapeuticsN/APREDPredictive Technology GroupN/ASOANAngioSoma0.02%Insider OwnershipCompanyInsider OwnershipHSTOHistogen3.30%OREXQOrexigen Therapeutics13.30%PREDPredictive Technology GroupN/ASOANAngioSomaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHSTOHistogen204.27 millionN/ANot OptionableOREXQOrexigen Therapeutics13218.89 millionN/ANot OptionablePREDPredictive Technology Group62316.67 millionN/ANot OptionableSOANAngioSomaN/A476.83 millionN/ANot OptionablePRED, HSTO, OREXQ, and SOAN HeadlinesRecent News About These CompaniesWatch: Unhygienic Making Process Of Soan Papdi Goes Viral, Leaves Internet DisgustedNovember 7, 2024 | food.ndtv.comFNational Security Adviser and Joint Chiefs Chair at U.S. Global Leadership ForumSeptember 19, 2024 | c-span.orgCC-SPAN TV ScheduleAugust 21, 2024 | c-span.orgCC-SPAN Radio ScheduleJuly 31, 2024 | c-span.orgCC-SPAN 2 TV ScheduleJuly 29, 2024 | c-span.orgCQ&A with Riley GainesJuly 19, 2024 | c-span.orgCSenate SessionApril 28, 2024 | c-span.orgCMartin SoanApril 22, 2024 | chortle.co.ukCDeath Clock / Life Span ClockApril 17, 2024 | medindia.netMWisconsin for KennedyApril 16, 2024 | c-span.orgCSinking of TitanicApril 1, 2024 | c-span.orgCSenator Laphonza Butler on Book BansMarch 29, 2024 | c-span.orgCAttention Span TestMarch 25, 2024 | psychologytoday.comPJane MarieMarch 17, 2024 | c-span.orgCThe ShowmanMarch 11, 2024 | c-span.orgCSuper Tuesday Primary ResultsMarch 6, 2024 | c-span.orgCSouth Carolina Republican Primary CoverageFebruary 25, 2024 | c-span.orgCGateway to StatesmanshipFebruary 25, 2024 | c-span.orgCAbout Books with Daniel PaisnerFebruary 23, 2024 | c-span.orgCLectures in History VideosFebruary 19, 2024 | c-span.orgCMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseWhy a Trump-Musk Feud Could Mean Big Wins for AST SpaceMobileBy Nathan Reiff | June 11, 2025View Why a Trump-Musk Feud Could Mean Big Wins for AST SpaceMobileMeta Pulls Ahead of the Mag 7: Analysts Predict a Breakout YearBy Leo Miller | June 10, 2025View Meta Pulls Ahead of the Mag 7: Analysts Predict a Breakout YearPRED, HSTO, OREXQ, and SOAN Company DescriptionsHistogen NASDAQ:HSTO$0.01 -0.01 (-43.50%) As of 06/27/2025Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California. On April 18, 2024, Histogen Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of California.Orexigen Therapeutics OTCMKTS:OREXQ$0.0053 +0.00 (+35.90%) As of 05/31/2019Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.Predictive Technology Group OTCMKTS:PREDPredictive Technology Group, Inc., together with its subsidiaries, develops and commercializes discoveries and technologies involved in novel molecular diagnostic, therapeutic, and human cellular and tissue-based products (HCT/Ps). It operates in two segments, Human Cellular and Tissues Products (HCT/Ps); and Diagnostics and Therapeutics. The company provides FertilityDX, a genetic testing service for couples experiencing infertility; ARTguide, a genetic test for women experiencing infertility because of endometriosis and other genetic conditions; and regenerative medicine products, including AmnioCyte, AmnioCyte Plus, PolyCyte, and CoreCyte for use in regenerative medicine applications. It has a collaboration agreement with Atrin Pharmaceuticals LLC to develop molecular diagnostic tools to facilitate enhanced selection of cancer patients. The company was formerly known as Global Enterprises Group, Inc. and changed its name to Predictive Technology Group, Inc. in July 2015. Predictive Technology Group, Inc. was founded in 2005 and is headquartered in Salt Lake City, Utah. On November 9, 2023, Predictive Technology Group, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Utah. On January 12, 2024, the voluntary petition of Predictive Technology Group, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on November 9, 2023.AngioSoma OTCMKTS:SOANAngioSoma, Inc., a wellness company, engages in the development and commercialization of dietary supplements to the medical, wellness, and adult-use markets. The company was founded in 2016 and is based in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Broadcom’s Big VMware Update: A Threat to Public Cloud Giants? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
